Stock Analysis of Oculis Holding AG (OCS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code OCS
Close 11.76
Change 0.070 / 0.599 %
Volume 3444.00
Vol Change -21313.00 / 86.09 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Oculis Holding AG
PE (TTM)

-7.30

Very Poor
Price / Book

7.23

Very Poor
Price / Sales

490.88

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

489800 K

Enterprise Value

451647 K

ROA (TTM)

-57.29

Very Poor
ROE (TTM)

-98.94

Very Poor
Net Margin (TTM)

-6721.69

Very Poor
Revenue

3.18 %

883000
Net Profit

129.47 %

-88802.00 K
Debt to Equity

0.0019

Excellent
Altman Z Score

10.15

Excellent
Quick Ratio

5.36

Very Good
Cash Ratio

4.80

Very Good


Highs/Lows of Oculis Holding AG
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week11.85 0.759 % 0.513 % 11.9511.6929-May-2430-May-24
Two Week11.975 1.80 % 0.486 % 12.079611.6921-May-2430-May-24
One Month13.07 10.02 % 4.80 % 13.0711.6902-May-2430-May-24
Three Month11.9 1.18 % 3.56 % 13.310.5530-Apr-2402-Apr-24
Six Months9.825 19.69 % 15.54 % 14.4659.625-Jan-2418-Dec-23
One year11.5 2.26 % 26.26 % 14.4959.0528-Aug-2301-Nov-23
Two year9.75 20.62 % 27.72 % 14.4956.2628-Aug-2327-Mar-23


Technical View of Oculis Holding AG
RSI

41.44

Neutral
MACD

-0.086

Bearish
ADX

10.84

Neutral
Super Trend

11.61

Mild Bullish
Williams %R

-90.14

Mild Bullish
CCI

-98.42

Neutral


EMA 5

11.81

Bearish
EMA 15

11.95

Mild Bearish
EMA 50

11.98

Strong Bearish
EMA 100

11.86

Whipsaw
SMA 100

12.01

Strong Bearish
SMA 200

11.57

Mild Bullish
SMA 5 / 20

11.83 / 12.08

Mild Bearish
SMA 15 / 50

11.94 / 11.92

Mild Bullish
SMA 50 / 200

11.92 / 11.57

Strong Bearish




Charts of Oculis Holding AG


Returns of Oculis Holding AG with Peers
Period / StockOCSKALVCABAAPLT
1 Week-0.759%3.27%-6.68%4.90%
1 Mth-10.02%2.82%-4.27%-3.17%
3 Mth-1.18%-14.51%-55.46%-39.89%
6mth19.69%38.27%-36.51%102.84%
1 Year2.26%19.69%0.991%231.78%
2 Year20.62%31.27%696.09%197.22%
5 Years--45.08%--56.72%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Oculis Holding AG with Peers
Ratio / StockOCSKALVCABAAPLT
PE-7.30-2794.60-5.86-900.47
P/B7.232200.072.5528494.91
ROA-57.29-67.71-40.22-298.98
ROE-98.94-78.73-43.45-3164.46
Debt To Equity0.00190.00680.0151-0.0250
Revenue883000
3.18 % 		0
% 		0
% 		10660.00 K
0 %
Net Income-88802.00 K
129.47 % 		-92907.00 K
12.83 % 		-67675.00 K
27.75 % 		-96513.00 K
16.97 %


Technicals of Oculis Holding AG with Peers
Technical / StockOCSKALVCABAAPLT-
ADX10.8416.8929.3912.12
CMF-0.3480.070-0.220-0.166
MFI20.7233.4935.1455.68
RSI41.4450.2833.2343.66
MACD Abv SignalFalseFalseFalseTrue
Price Above 50 MAFalseTrueFalseFalse-
Price Above 200 MATrueTrueFalseTrue-


About : Oculis Holding AG Ordinary shares

Address : Bahnhofstrasse 7, Zug, Switzerland, 6300
Tel : 41 41 711 9325
URL : https://oculis.com
Code : OCS, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 02_Mar_2023
Employee Count : 36

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.


Note : All Data Generated at the End of Trading Hours (EOD Data)